2 results
Approved WMORecruiting
The PLANCTON trial will investigate the effect of early intravenous OM-3 FAs on new onset organ failure and mortality in patients with predicted SAP.
Approved WMOWill not start
Primary:To estimate the treatment effect of emactuzumab on objective response rate (ORR) by 6 months from initiation of therapy in the blinded phase compared to placeboSecondary:the effect of emactuzumab on clinical outcome assessments (COAs) for:o…